logo BDSP

Base documentaire

  1. Value of maternal serum unconjutated oestriol measurement in prenatal screening for down's syndrome.

    Article - En anglais

    We compared the medical and financial cost-effectiveness of prenatal serum screening for Down's syndrome using maternal age, serum alpha-fetoprotein and human chorionic gonadotrophin with and without the use of unconjugated oestriol.

    The use of unconjugated oestriol is medically more cost-effective than screening without it at all levels of detection.

    The actual performance depends on whether gestational age is estimated using « dates » or an ultrasound scan.

    At a detection rate of 60 per cent, the proportion of unaffected fetal losses per case diagnosed at amniocentesis is about 22 per cent less if gestational age is estimated using dates (time since the first day of the last menstrual period) and about 47 per cent less if it is based on an ultrasound scan examination.

    Mots-clés Pascal : Oestriol, Exploration hormonale, Diagnostic, Prénatal, Dépistage, Foetus, Chromosome G21, Trisomie, Aneuploïdie, Aberration chromosomique, Homme, Rapport coût bénéfice, Programme sanitaire, Royaume Uni, Europe, Mère, Oestrogène, Hormone stéroïde sexuelle, Hormone ovarienne, Foetus pathologie

    Mots-clés Pascal anglais : Estriol, Hormonal investigation, Diagnosis, Prenatal, Medical screening, Fetus, G21-Chromosome, Trisomy, Aneuploidy, Chromosomal aberration, Human, Cost benefit ratio, Sanitary program, United Kingdom, Europe, Mother, Estrogen, Sex steroid hormone, Ovarian hormone, Fetal diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0631415

    Code Inist : 002B20F01. Création : 09/06/1995.